REGN vs RM · P/E 14, rev $14.34B vs P/E 7.5, rev $588.5M
Regeneron Pharmaceuticals Inc (REGN) versus Regional Management Corp (RM) — a side-by-side from cached financials, not a winner call.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Regional Management Corp (RM) is a credit services company listed on NYSE.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Latest reported RM revenue for 2024-12-31 was $588.5M. Net income was $41.2M. Revenue was up 6.7% from 2023-12-31 to 2024-12-31. RM currently screens at market cap $339.8M and trailing P/E 7.5.
REGN currently screens at market cap $59.10B and trailing P/E 13.9. RM currently screens at market cap $339.8M and trailing P/E 7.5.
Not investment advice. Open the REGN and RM stock pages for the full models.
Not investment advice.